Biosplice Therapeutics

Biosplice Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 by Osman Kibar and known until its 2020 rename as Samumed, LLC (samumed.com still redirects to biosplice.com). The company develops first-in-class small-molecule therapeutics that act on novel components of the Wnt signaling pathway and on the regulation of alternative pre-mRNA splicing. Its lead program is lorecivivint, an investigational intra-articular knee injection for osteoarthritis, positioned against a stated unmet need of "over 50 million US patients suffer from osteoarthritis, with no drugs available to arrest the disease"; the candidate has completed Phase 3 study and a New Drug Application has been submitted to the U.S. Food and Drug Administration. Programs outside lorecivivint — neurology, diabetes and oncology — are developed by the company's affiliate TenaRx, Inc. The company is led by Erich Horsley (Chief Executive Officer) with Osman Kibar as Founder and Executive Chairman, Yusuf Yazici as Chief Medical Officer, Phil Wilson as Chief Financial Officer and Scott W. Bulcao as Chief Legal Officer. Biosplice is a drug-discovery and clinical-development organization, not a software vendor: biosplice.com is a small ASP.NET corporate site covering mission, board, management, advisors, programs, publications, news and careers, and the company publishes no developer program of any kind — no API, no SDK, no developer portal, no GitHub organization and no machine-readable API contract.

Biosplice Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Development.

Biosplice Therapeutics’ developer surface includes product news, engineering blog, support, and 14 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesDrug DevelopmentClinical TrialsOsteoarthritisSmall Molecule TherapeuticsHealth CareSan Diego

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 11.9/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 1.1 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.6 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/biosplice-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact

Contact

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 6

The organization behind the API

Website

About

News

Blog

Careers

LinkedIn

Other 4

Properties that don't map to a standard resource type

Pipeline

Team

Publications

SecondaryMarket

Source (apis.yml)

aid: biosplice-therapeutics
name: Biosplice Therapeutics
description: 'Biosplice Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in
  San Diego, California, founded in 2008 by Osman Kibar and known until its 2020 rename as Samumed, LLC (samumed.com still
  redirects to biosplice.com). The company develops first-in-class small-molecule therapeutics that act on novel components
  of the Wnt signaling pathway and on the regulation of alternative pre-mRNA splicing. Its lead program is lorecivivint, an
  investigational intra-articular knee injection for osteoarthritis, positioned against a stated unmet need of "over 50 million
  US patients suffer from osteoarthritis, with no drugs available to arrest the disease"; the candidate has completed Phase
  3 study and a New Drug Application has been submitted to the U.S. Food and Drug Administration. Programs outside lorecivivint
  — neurology, diabetes and oncology — are developed by the company''s affiliate TenaRx, Inc. The company is led by Erich
  Horsley (Chief Executive Officer) with Osman Kibar as Founder and Executive Chairman, Yusuf Yazici as Chief Medical Officer,
  Phil Wilson as Chief Financial Officer and Scott W. Bulcao as Chief Legal Officer. Biosplice is a drug-discovery and clinical-development
  organization, not a software vendor: biosplice.com is a small ASP.NET corporate site covering mission, board, management,
  advisors, programs, publications, news and careers, and the company publishes no developer program of any kind — no API,
  no SDK, no developer portal, no GitHub organization and no machine-readable API contract.'
url: https://raw.githubusercontent.com/api-evangelist/biosplice-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-07'
modified: '2026-08-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Development
- Clinical Trials
- Osteoarthritis
- Small Molecule Therapeutics
- Health Care
- San Diego
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/biosplice-therapeutics-domain-security.yml
- type: WellKnown
  url: well-known/biosplice-therapeutics-well-known.yml
- type: LLMsTxt
  url: llms/biosplice-therapeutics-llms.txt
- type: Website
  url: https://www.biosplice.com/
- type: About
  url: https://www.biosplice.com/mission/default.aspx
- type: Pipeline
  url: https://www.biosplice.com/our-programs/detail.aspx?id=20
- type: Team
  url: https://www.biosplice.com/management/default.aspx
- type: Publications
  url: https://www.biosplice.com/publications/default.aspx
- type: News
  url: https://www.biosplice.com/news/default.aspx
- type: Blog
  url: https://www.biosplice.com/news/default.aspx
- type: Careers
  url: https://www.biosplice.com/careers/default.aspx
- type: Contact
  url: https://www.biosplice.com/contact-us/default.aspx
- type: Support
  url: https://www.biosplice.com/contact-us/default.aspx
- type: PrivacyPolicy
  url: https://www.biosplice.com/privacy/default.aspx
- type: TermsOfService
  url: https://www.biosplice.com/terms/default.aspx
- type: LinkedIn
  url: https://www.linkedin.com/company/biospliceinc
- type: SecondaryMarket
  url: https://forgeglobal.com/biosplice-therapeutics_stock/
x-enrichment:
  date: '2026-08-07'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Biosplice is a clinical-stage drug developer whose product is an injectable small molecule, not software; www.biosplice.com
    is a 13KB ASP.NET brochure site with no robots.txt and no sitemap.xml, every spec and /.well-known/ path is rewritten
    to the CMS 404 page, and api./developer./docs./portal./status./graphql./mcp.biosplice.com have no DNS record at all.
  evidence:
  - url: https://www.biosplice.com/openapi.json
    status: 404
  - url: https://www.biosplice.com/.well-known/agent-card.json
    status: 404
  - url: https://www.biosplice.com/.well-known/agent.json
    status: 404
  - url: https://www.biosplice.com/llms.txt
    status: 404
  - url: https://www.biosplice.com/sitemap.xml
    status: 404
  - url: https://api.github.com/orgs/biosplice
    status: 404
  checked: '2026-08-07'